Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06880107

Genetic Variants of Annexin A2 and Cryptogenic Stroke

Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Genetic variants of tPA and PAI-1 genes have been suggested to be the risk factors for stroke.

ANXA2 plays a pivotal role in plasmin generation and fibrinolysis. Several studies showed the role of ANXA2 and S100A10 subunits in regulation of fibrinolysis in vivo. Recently, the efficacy of recombinant ANXA2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. Some single nucleotide polymorphisms in ANXA2 gene could be associated with increased risk of stroke in sickle cell disease.

Therefore, these data invite us to test hypothesis that genetic variants of ANXA2 gene could be associated with ischemic stroke.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Annexin A2 Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Fibrinolysis Genetic Variants of Host Nervous System Diseases Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHRU Amiens

Amiens, 80054, France

Location status: Recruiting

Location contact

Audrey ARNOUX COURSELLE, MD

SUB_INVESTIGATOR

Chantal LAMY, MD

SUB_INVESTIGATOR

Estelle CADET, rPH

SUB_INVESTIGATOR

Olivier GODEFROY, Pr

SUB_INVESTIGATOR

Sandrine CANAPLE, MD

SUB_INVESTIGATOR

Valéry Salle, MD

CONTACT

[email protected]

33+3 22 66 82 30

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients
  • Age from 18 years old

Exclusion criteria

  • Transient ischemic attack
  • Pregnancy

Treatment and study plan

blood withdrawal

Biological

blood withdrawal

Primary outcomes

  1. genetic variants of ANXA2

    Time frame: day 1

  2. genetic variants of S100A10

    Time frame: day 1

Secondary outcomes

  1. blood ANXA2 concentration

    Time frame: day 1

  2. blood S100A10 concentration

    Time frame: day 1

  3. concentration of Autoantibodies directed against ANXA2

    Time frame: day 1

  4. concentration of S100A10 directed against ANXA2

    Time frame: day 1

Study contacts

Contact information is provided by the study sponsor or research team.

Valéry SALLE, MD

CONTACT

[email protected]

33+3 22 66 82 30

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: GENANXVA

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Mar 17, 2025
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.